

**Title: Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses**

Authors names and affiliations:

David A. Muller<sup>1,2</sup>, Frances E. Pearson<sup>1</sup>, Germain J.P. Fernando<sup>1,2</sup>, Christiana Agyei-Yeboah<sup>1</sup>, Nick S. Owens<sup>1</sup>, Simon R. Corrie<sup>1,2</sup>, Michael L. Crichton<sup>1</sup>, Jonathon C.J. Wei<sup>1</sup>, William C. Weldon<sup>3</sup>, M. Steven Oberste<sup>3</sup>, Paul R. Young<sup>2,4</sup>, Mark A. F. Kendall<sup>1,2\*</sup>.

<sup>1</sup>Delivery of Drugs and Genes Group (D<sup>2</sup>G<sup>2</sup>), Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland, Australia.

<sup>2</sup>Australian Infectious Diseases Research Centre, The University of Queensland, Brisbane, Queensland, Australia.

<sup>3</sup>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

<sup>4</sup>School of Chemical and Molecular Biosciences, The University of Queensland, Brisbane, Queensland, Australia.


**\*Corresponding author:** Professor Mark Kendall

Address: The University of Queensland, Delivery of Drugs and Genes Group, Australian Institute for Bioengineering and Nanotechnology, Building 75, St Lucia, Queensland, 4072. Australia

Tel: +61 7 334 64203 Fax: +61 7 334 64197

Email: [m.kendall@uq.edu.au](mailto:m.kendall@uq.edu.au)

Supplementary data:



**Figure S1: Neutralising antibody titres prior to immunisation.** Seropositivity was defined as a titre  $\geq 3.0 \log_2$  (the dotted line)